Clinical Trial Results: IT-hu14.18-IL2 With Radiation, Nivolumab and Ipilimumab for Melanoma [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 trial evaluating IT-hu14.18-IL2 with radiation, nivolumab and ipilimumab in melanoma; study terminated with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Melanoma

Drugs mentioned

• IT-hu14.18-IL2
• ipilimumab (ipilimumab)
• nivolumab (nivolumab)

Snippet

Sponsor: University of Wisconsin, Madison | Conditions: Melanoma | Phase 1, Phase 2 | Status: TERMINATED | Results posted: 2026-06-03